Skip to content
Screener

Exelixis EXEL Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$201M+8.6%
Pfizer logo
PfizerPFE
$272M+60.0%
Kura Oncology logo
Kura OncologyKURA
$8.42M+7.3%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$10.8M+48.8%
Immunome logo
ImmunomeIMNM
$7.95M+39.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$15M0.0%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$12.93B+27.4%
Enterprise value$12.82B+26.1%
P/E15×-1.8×
P/S5.3×+0.8×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net income$422,517$344,464
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization13,93214,687
Stock-based compensation61,61362,001
Non-cash lease expense11,92112,166
Acquired in-process research and development technology10,600750
Other, net(3,295)(10,617)
Changes in operating assets and liabilities:

Item 1. Financial Statements.

FAQ

What is Exelixis's stock-based comp?
Exelixis (EXEL) reported stock-based comp of $32.56M in Q2 2026.
How has Exelixis's stock-based comp changed year-over-year?
Exelixis's stock-based comp decreased by 9.7% year-over-year, from $36.07M to $32.56M.
What is the long-term trend for Exelixis's stock-based comp?
Over 4 years (2021 to 2025), Exelixis's stock-based comp has grown at a -1.5% compound annual growth rate (CAGR), from $119.82M to $112.98M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Exelixis's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude